ライフサイエンスコーパス: uncompetitive

1 o3S4, thus rendering full cell energetically uncompetitive.

2 ism of open-channel blockade by memantine is uncompetitive.

3 itive at low drug concentrations and MPyr is uncompetitive.

4 -CoA inhibition of CPT-I from competitive to uncompetitive.

5 high AdoMet concentrations, the pattern was uncompetitive.

6 Kg dead-end analogues, respectively, and are uncompetitive against NADH and noncompetitive against al

7 subsaturating cosubstrate concentration and uncompetitive against preQ(1)-tRNA(Tyr) when AdoMet was

8 The use of uncompetitive (also called anticompetitive) inhibitors i

9 the ordered kinetic mechanism desulfo-CoA is uncompetitive and citrate is competitive vs alpha-ketogl

10 The conjunction of the uncompetitive and competitive modes of inhibition indica

11 er, we offer exact mathematical solutions to uncompetitive and non-competitive inhibition, and demons

12 Lithium acts as both an uncompetitive and non-competitive inhibitor of several l

13 culations) find the metallic structure to be uncompetitive, and predict a phase diagram in reasonable

14 al neurotransmission, in part because of its uncompetitive antagonism with a fast off-rate.

15 microM memantine was close to ideal for pure uncompetitive antagonism.

16 kade of the N-methyl-D-aspartate receptor by uncompetitive antagonists has implications for symptomat

17 49 --> Leu and Arg49 --> Asp mutants) and to uncompetitive (Arg49 --> Cys mutant).

18 competitive behavior with respect to ATP and uncompetitive behavior with respect to AMP resulting in

19 type with prominent (ca. 60 % of inhibition) uncompetitive characteristics and an IC50 of 0.8 muM und

20 An uncompetitive component with a Ki ' of 11 mM was also fo

21 ine was evaluated for non-competitive and/or uncompetitive components of antagonism.

22 tration increases, the inhibition changes to uncompetitive, consistent with a steady state random mec

23 s primarily an uncompetitive inhibitor, with uncompetitive constant K(i)' = 37 mM and Cl(-)-competiti

24 MYEL assay can also identify competitive and uncompetitive Epac inhibitors, e.g. (Rp)-cAMPS and CE3F4

25 nol-1 and ubiquinol-2 inhibit turnover in an uncompetitive fashion.

26 FDA-approved drug memantine, representing an uncompetitive/fast off-rate antagonist of NMDA-type glut

27 In contrast, inhibition is uncompetitive for the ibuprofen-ester substrate, consist

28 ereas the inhibition kinetics is found to be uncompetitive in terms of Q2.

29 ibition (ATP-competitive, noncompetitive, or uncompetitive) in PoA compared to IoC or show a change i

30 etitive inhibition (decreased V max), whilst uncompetitive inhibition (decreased V max and K m ) occu

31 could be fit with the equation for complete uncompetitive inhibition and that the mechanism may be a

32 The uncompetitive inhibition and the substrate-dependent bin

33 Theoretically, uncompetitive inhibition arises from preferential intera

34 Uncompetitive inhibition by arabinose 5-phosphate (Ara5P

35 pentameric complex, which suggests that the uncompetitive inhibition by BFA and the nucleotide allos

36 Finally, we note that the apparent uncompetitive inhibition by fluoride as reported for sev

37 constant (K(ic)) of 0.12 +/- 0.02 mM and an uncompetitive inhibition constant (K(iu)) of 3.04 +/- 0.

38 how unimpaired inhibition by triclosan, with uncompetitive inhibition constants (K(i)') of 0.18+/-0.0

39 Compound 4 shows a mix of competitive and uncompetitive inhibition for both the yeast and the huma

40 utant protease showed mixed-type competitive-uncompetitive inhibition for darunavir and the chemicall

41 inding of agonists to Epac1 and suggested an uncompetitive inhibition mechanism with respect to Epac1

42 ligand binding and kinetic data best fit an uncompetitive inhibition model in which the binding of t

43 lowed by naphthol substrate, as shown by the uncompetitive inhibition of 3HNR by tricyclazole with re

44 o importantly, binding to this pocket causes uncompetitive inhibition of KSP ATPase activity.

45 For this purpose, only uncompetitive inhibition of pyruvate export proves effec

46 An uncompetitive inhibition of the anaerobic reaction catal

47 m and Vmax values, suggesting a mechanism of uncompetitive inhibition on GlyT1-mediated glycine uptak

48 This uncompetitive inhibition suggests that the probe can int

49 -L-arginine was synthesized and demonstrated uncompetitive inhibition versus ATP and competitive patt

50 d competitive inhibition vs saccharopine and uncompetitive inhibition vs NADP.

51 Uncompetitive inhibition was also observed with the synt

52 ns of agonist for "pure' non-competitive vs. uncompetitive inhibition was computer simulated.

53 is unknown, the structural requirements for uncompetitive inhibition were investigated by applicatio

54 ding a series of parallel plots, typical for uncompetitive inhibition with a Ki for inhibition of app

55 The uncompetitive inhibition with respect to ATP is also con

56 calpains relative to other proteases, (iii) uncompetitive inhibition with respect to substrate, and

57 re also provided for competitive inhibition, uncompetitive inhibition, and mixed inhibition of ordere

58 The appearance of uncompetitive inhibition, however, suggests that a more

59 RFA-P showed uncompetitive inhibition, K(i) = 0.210 mm, under varied

60 CO(2) showed uncompetitive inhibition, K(i) = 0.990 mm, under varied

61 At the concentrations corresponding to uncompetitive inhibition, PDPA shows positive cooperativ

62 for Ca(2+) that mediated noncompetitive and uncompetitive inhibition, respectively.

63 with urease is not compatible with classical uncompetitive inhibition.

64 han), an effector (3-indole ethanol), and an uncompetitive inhibitor (Mitomycin C).

65 Fosmidomycin was an uncompetitive inhibitor against NADPH and gave a pattern

66 ydroxylauroyl-methylphosphopantetheine is an uncompetitive inhibitor against R-3-OHC14-ACP and a comp

67 o 6983 or bisindolylmaleimide I, but not the uncompetitive inhibitor bisindolylmaleimide IV, prevents

68 The uncompetitive inhibitor Li+ causes little change in the

69 of 6.0 and 9.0, fluoride ion acts as a pure uncompetitive inhibitor of AAP, and the Ki increases fro

70 At low concentrations cystamine is an uncompetitive inhibitor of caspase-3 activity, becoming

71 l derivatives of the steroid DHEA 1, a known uncompetitive inhibitor of G6PD, were designed, synthesi

72 We also found that gamma-boroGlu is an uncompetitive inhibitor of Gly-Gly-promoted transamidati

73 A prototypic uncompetitive inhibitor of IMPDH, mycophenolic acid (MPA

74 We show that NaF is an uncompetitive inhibitor of MshB, consistent with a metal

75 The substrate APS acts as a strong uncompetitive inhibitor of the APS kinase reaction.

76 dies showed that TPBC is a highly efficient, uncompetitive inhibitor of the bacterial pyruvate dehydr

77 The drug brefeldin A (BFA), an uncompetitive inhibitor of the exchange reaction that bi

78 ith respect to nicked DNA, whereas L82 is an uncompetitive inhibitor that stabilized complex formatio

79 This inhibitor was found to be an uncompetitive inhibitor to CoA and a mixed-type inhibito

80 mpetitive inhibitor versus tryptamine and an uncompetitive inhibitor versus acetyl-CoA, indicative of

81 etitive inhibitor versus cycloartenol and an uncompetitive inhibitor versus AdoMet.

82 Pyruvate functioned as an uncompetitive inhibitor versus ATP, and inclusion of ADP

83 Acetaldehyde is an uncompetitive inhibitor versus oxygen, indicating that a

84 tial velocity studies show that IIAGlc is an uncompetitive inhibitor with respect to both substrates,

85 d that benzyl isocyanide was the most potent uncompetitive inhibitor with respect to heme with a KI =

86 titive inhibitor with respect to NADH and an uncompetitive inhibitor with respect to the substrate 2-

87 tudied the binding of fluoride ion (F(-); an uncompetitive inhibitor) and L-arginine, L-valine, dinor

88 strate, inosine monophosphate (IMP), and the uncompetitive inhibitor, mycophenolic acid, to inosine m

89 PPi is a linear uncompetitive inhibitor, suggesting that it dissociates

90 ntrations lower than 0.25 microM, PDPA is an uncompetitive inhibitor, while at PDPA concentrations hi

91 act PSII revealed that I(-) was primarily an uncompetitive inhibitor, with uncompetitive constant K(i

92 s may have facilitated the discovery of this uncompetitive inhibitor.

93 zyme-substrate complex, Topotecan acts as an uncompetitive inhibitor.

94 ol dehydrogenase-NADH complex and are potent uncompetitive inhibitors against alcohol.

95 They are uncompetitive inhibitors against varied concentrations o

96 They bind to the enzyme-NADH complex and are uncompetitive inhibitors against varied concentrations o

97 Using uncompetitive inhibitors of ALPs and fluorescent D-tetra

98 t contain D-ArgNO2 (8-10, 12, 13), which are uncompetitive inhibitors of iNOS but competitive inhibit

99 ate kinetics, we have shown that halides are uncompetitive inhibitors of XaDHL with 1, 2-dichloroetha

100 s were competitive inhibitors versus ATP and uncompetitive inhibitors versus GST-ATF2.

101 to be competitive inhibitors against NAD and uncompetitive inhibitors with respect to aldehyde.

102 nhibition model (behaving closely to that of uncompetitive inhibitors) when evaluated spectrophotomet

103 These compounds are uncompetitive inhibitors, binding the gamma-glutamyl enz

104 Using two model ATP-uncompetitive inhibitors, monastrol and ispinesib, we re

105 sing basis for the systematic design of such uncompetitive inhibitors.

106 l shikimic acids both act as competitive and uncompetitive inhibitors.

107 Although ketamine has unequivocal uncompetitive inhibitory effects on N-methyl-d-aspartate

108 Then we explored the uncompetitive inhibitory mechanism of brefeldin A (BFA)

109 er varied PRPP and saturated pABA, and again uncompetitive, K(i) = 0.300 mm, under saturated PRPP and

110 ighly reduced K(m) and V(max) reminiscent of uncompetitive kinetics with 4-cholesten-7alpha-ol-3-one

111 treat multiple sclerosis, inhibits ATX in an uncompetitive manner and slows the hydrolysis reaction,

112 the glutamine acceptor dimethylcasein in an uncompetitive manner with respect to dimethylcasein util

113 led that LOX-PP inhibits FGF-2 binding in an uncompetitive manner.

114 tor is selective for APEH, shows an uncommon uncompetitive mechanism of inhibition, and in solution a

115 er in the inhibitor structure resulted in an uncompetitive mechanism of inhibition, which further res

116 + lowered both the Vmax and Km of SGC via an uncompetitive mechanism through direct interaction with

117 ng starch as the substrate, HPA exhibited an uncompetitive mode of inhibition with an apparent K(i) o

118 Providing biochemical support for an uncompetitive mode of inhibition, in vitro binding studi

119 was to evaluate the effects of MRZ 2/579, an uncompetitive N-methyl-D-aspartate antagonist, on infarc

120 The uncompetitive N-methyl-D-aspartate receptor (NMDAR) anta

121 ine, a low to moderate affinity open channel uncompetitive N-Methyl-d-aspartate receptor antagonist,

122 Memantine is a low- to moderate-affinity, uncompetitive N-methyl-D-aspartate receptor antagonist.

123 The uncompetitive NMDA antagonist AR-R15896AR inhibited effl

124 These results suggest that uncompetitive NMDA antagonists, more specifically open c

125 effect commonly produced by competitive and uncompetitive NMDA antagonists.

126 study was to characterize the effects of the uncompetitive NMDA receptor antagonist memantine on pala

127 n sheath formed by oligodendrocytes, that an uncompetitive NMDAR antagonist has successfully passed h

128 Furthermore, the uncompetitive NMDAR antagonist memantine attenuates NMDA

129 nduced by mitochondrial dysfunction and that uncompetitive NMDAR blockade may be used as a neuroprote

130 We tested the hypothesis that uncompetitive NMDAR blockade with memantine prevents mit

131 was apparently competitive versus AdoMet and uncompetitive/noncompetitive versus DNA at </=20 microM

132 also how this can lead to a noncompetitive, uncompetitive or cooperative binding mechanism.

133 in many cases is achieved via a competitive, uncompetitive or non-competitive mechanism.

134 arying concentrations of dansyl-GCIIL and an uncompetitive pattern against GGPP.

135 An uncompetitive pattern is also obtained with dPFK for Ara

136 ibition by phosphopeptide product yielded an uncompetitive pattern when ATP was the varied substrate.

137 ptide concentrations yielded parallel lines (uncompetitive pattern).

138 bind in the active site yet exhibit non- or uncompetitive patterns of inhibition.

139 hium chloride, which has been reported to be uncompetitive, remains unchanged.

140 The weaker uncompetitive site suggests the existence of a transient

141 was estimated as 1 mM, and the K(i)' for the uncompetitive site was estimated as 8 mM.

142 the active site but also to bind to a second uncompetitive site.

143 In addition, uncompetitive substrate inhibition by alpha-Kg and doubl

144 Data are consistent with uncompetitive substrate inhibition by naphthol as a resu

145 of purealin was concentration dependent and uncompetitive, supporting the hypothesis that it does no

146 Their mechanism of inhibition is uncompetitive toward both the peptide substrate and NAD(

147 Inhibition by GlcNAc-GlcNAc-P-P-dolichol was uncompetitive toward UDP-GlcNAc and competitive toward d

148 H3-20 K14A was competitive versus H3-20 and uncompetitive versus acetyl-CoA.

149 enol was competitive versus cycloartenol and uncompetitive versus AdoMet.

150 s demonstrate that l-histidine inhibition is uncompetitive versus ATP and noncompetitive versus PRPP.

151 oncompetitive versus ubiquinone and both are uncompetitive versus DHO.

152 Product inhibition by saccharopine is uncompetitive versus NADH, suggesting a practical irreve

153 Inhibition by methionine was uncompetitive versus preQ(1)-tRNA(Tyr), but noncompetiti

154 tamate and is competitive vs L-glutamate and uncompetitive vs L-AASA and NADPH.

155 L-AASA is noncompetitive vs saccharopine and uncompetitive vs NADP.

156 alogue of L-AASA and is competitive vs AASA, uncompetitive vs NADPH, and noncompetitive vs L-glutamat

157 eak rate) will determine the contribution of uncompetitive vs. non-competitive actions, respectively.

158 netic field renders the overall logic scheme uncompetitive when compared with complementary metal-oxi

159 ition; inhibition by inorganic phosphate was uncompetitive, whereas inhibition by fructose 6-phosphat

160 he inhibition type for RPE65 was found to be uncompetitive with K(i) = 53 mum.

161 4+/-0.9 microM, while inhibition of A124V is uncompetitive with K(i)' = 0.81 +/- 0.11 microM.

162 plex, we find that the inhibitory peptide is uncompetitive with regard to SAM.

163 ncompetitive inhibitor versus tryptamine and uncompetitive with respect to acetyl-CoA.

164 Inhibition was reversible, uncompetitive with respect to ATP, and non-competitive w

165 on-competitive with syntide-2 substrate, and uncompetitive with respect to ATP.

166 Binding of triclosan to wild-type InhA is uncompetitive with respect to both NADH and trans-2-dode

167 te, noncompetitive with respect to Mg2+, and uncompetitive with respect to fructose 1,6-bisphosphate.

168 is competitive with respect to phosphite and uncompetitive with respect to NAD(+).

169 itor with respect to glucose 1-phosphate and uncompetitive with respect to phosphate.

170 activation of catalysis by these amines was uncompetitive with respect to superoxide, interpreted as

171 s competitive with the protein substrate and uncompetitive with the isoprenoid substrate; the Ki for

172 Because they are uncompetitive with the substrate, halide ions do not bin